This contract notice invites interested operators to submit tenders to a procurement.

The procurement aims to trigger new solutions to be developed and tested to address the challenge of the rising incidence of hypertension and the need for more effective management by empowering patients and the healthcare professionals involved in their care.

The procurement should address the procurers' unmet needs relating to different aspects (building blocks) of hypertension care: early detection and prevention, healthier lifestyle and nutrition, optimised drug therapy and improving treatment adherence, use of devices and remote monitoring, personalised decision support, interoperability and integration, quality and outcome reporting, patient-professional collaboration and co-ordination, training and education.

More information can be found on the HSMonitor website: https://hsmonitor-pcp.eu/

The procurement will take the form of a pre-commercial procurement (PCP) under which R&D service contracts will be awarded to R&D providers in parallel in a phased approach. This will make it possible to compare competing alternative solutions. Each selected operator will be awarded a framework agreement that covers three R&D phases. For each phase, a specific contract will be concluded with the selected operators. The three phases are: solution design, prototype development, original development and validation and testing of a limited volume of first products or services. After each phase, intermediate evaluations will be carried out to select the best of the competing solutions. The contractors with the best value-for-money solutions will be offered a specific contract for the next phase.

The selected operators will retain ownership of the intellectual property rights (IPRs) that they generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions.